Whalesbook
Zydus Lifesciences ne machaya dhamal, share pahuncha record high par!
Zydus Lifesciences ke investors ki toh aaj mauj aa gayi! Company ka stock ₹1,083 ke all-time high par pahunch gaya, jo ki 6.3% ka badhotari hai. Ye sab FY26 ke Q4 mein company ke zabardast performance ki wajah se hua. Unhone ₹7,587 crore ka revenue report kiya, jo pichle saal se 16% zyada hai. Is growth mein U.S. aur MedTech segments ka sabse bada hath raha.
Company ne ₹397.5 crore ka Mirabegron litigation settlement ka one-time charge bhi manage kar liya, fir bhi unka adjusted net profit 15% badhkar ₹1,592.9 crore ho gaya. Unka EBITDA bhi 20% bada aur EBITDA margin 110 basis points sudhar kar 33.7% ho gaya. Investors ka confidence badhane ke liye, board ne ₹1,100 crore ka share buyback bhi approve kiya hai ₹1,150 per share ke rate par aur FY26 ke liye 100% dividend bhi announce kiya hai.
Analysts kya bol rahe hain? Thoda positive, thoda cautious
Brokerage firms ne Zydus ke results ko pasand kiya hai, lekin unke views thode mixed hain. Nuvama ne rating ko 'HOLD' mein upgrade kiya aur target price badha kar ₹1,050 kar diya. Unka kehna hai ki 16% se zyada revenue growth aur 74% ka strong gross margin dikh raha hai. Nuvama ko specialty products, MedTech integration aur biologics se aur margin improvement ki umeed hai. Lekin, unhone FY27 aur FY28 ke liye U.S. revenue mein flat growth ka estimate diya hai, jisme specialty segment mein FY28 tak recovery hogi.
Motilal Oswal ne 'Neutral' rating maintain ki hai aur target price ko badha kar ₹1,080 kar diya hai. Unke hisaab se India aur emerging markets mein growth, U.S. business mein moderating pace ko balance kar rahi hai. Motilal Oswal ko India aur emerging markets se double-digit revenue growth ki umeed hai jo U.S. aur API sales ko compensate karegi. Unhone FY27 aur FY28 ke earnings estimates ko bhi 5% aur 4% badhaya hai. Zydus Lifesciences ki market cap lagbhag ₹1.2 trillion hai.
U.S. Market aur Margin Sustainability: Kya hai rishta?
Share price aur earnings toh badhiya hain, par Zydus Lifesciences ko kuch challenges face karne pad sakte hain. U.S. market mein aane wali slowdown, jo company ka ek bada revenue source hai, ek significant risk ho sakta hai. Nuvama ka forecast ki agle do saal U.S. revenue flat rahega, ye dikhata hai ki is critical market mein growth laana mushkil ho sakta hai. Agar growth expectations poori nahi hui toh overvaluation ka dar bhi hai.
Iske alawa, margins improve hue hain, par competition aur badalti pharmaceutical regulations ke beech is expansion ko maintain karna dekhne wali baat hogi. Litigation settlement ek reminder hai ki future mein kuch anjane kharche aa sakte hain jo profitability ko affect kar sakte hain.